paroxysmal atrial fibrillation
Conditions
Interventions
Memantine treatment group:Memantine treatment
Propafenone treatment group:Propafenone treatment
Sponsors
East Hospital, Tongji University School of Medicine; Army Specialty Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, male or female, Han nationality; 2. Had at least one episode of atrial fibrillation detected on electrocardiography within 3 months and maintained sinus rhythm for at least 1 hour before randomization. 3. Voluntarily participate in the trial, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. History of cardiovascular and cerebrovascular diseases; Ischemic events (stroke and TIA) within the last 6 months; history of cardiac surgery, history of myocardial infarction(MI),history of coronary intervention (PCI) within the last 6 months; Hypertrophic cardiomyopathy (ventricular septal or back wall > 18 mm); LVEF55mm; Congenital heart disease; After artificial heart valve replacement; History of left atrial ablation or left atrial surgery; Atrial thrombus; Other antiarrhythmic drugs have been administered recently; Sick sinus syndrome without permanent artificial pacemaker implantation; Second degree or higher atrioventricular block; Double bundle branch block; 2. Severe comorbidities: Active hepatitis or significant chronic liver disease or severe liver damage; Severe renal insufficiency (eGFR<30ml/min/1.73m^2); 3. Circumstances that would preclude enrollment in a clinical trial: Are participating or are expected to participate in any other clinical trial; Patients who were willing to undergo catheter ablation of atrial fibrillation; Have received treatment with a trial drug or device from another protocol within the past 1 month; Pregnant and lactating women; Women who have fertility requirements within the past one year; Reversible causes of atrial fibrillation; Such as hyperthyroidism, cardiothoracic surgery; A history of epilepsy, mental illness or depression; Known allergy to any drugs that may be used in the study (memantine and propafenone); Unwillingness or inability to fully comply with study procedures or follow-up requirements, or any other reason that the researcher believes would put the patient at greater risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of first recurrence of atrial fibrillation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tachycardia related symptoms recurred for the first time;Load of atrial fibrillation/atrial flutter/atrial tachycardia;life quality score; | — |
Countries
China
Contacts
Public ContactYihan Chen/ Chunyu Zeng
East Hospital, Tongji University School of Medicine/ Army Specialty Medical Center
Outcome results
None listed